Pharmaceutical Industry: medical reform and the integration of assets through 20
Pharmaceutical manufacturing industry from January to November 2009, operating income, total profits were 796.4 billion, 80.8 billion, up 21.37%, 25.24%; gross margin decreased slightly (30.67% from January to November, 2009, 2008, 1-11 30.69% month), Sell Profit margins have rebounded somewhat (from January to November 2009, 10.15%, 9.83% from January to November 2008).
From the sub-industry perspective, from January to November 2009, chemical medicine preparation revenues increased 26.62% year on year, gross profit increased 26.92% year on year; Chemistry API Operating income increased 10.68% year on year, gross profit increased 8.64% year on year; proprietary operating income increased 19.65% year on year, gross profit increased 24.70% year on year; bio-pharmaceutical revenues increased 17.18% year on year, gross profit increased 35.29% year on year.
-Year growth rate of speed, strength biopharmaceutical
As of April 28, 2010, our survey of the 108 annual reports published in 2009 the pharmaceutical companies, the overall operating income, net profit attributable to parent company, good condition, respectively, an increase of 14.92%, 48.59%; hair rate risen moderately (30.34% in 2009, was 29.59% in 2008), sales profit rate of increase (11.79% in 2009, 2008, 8.93%). Plate overall performance of the macro data with the pharmaceutical industry trend is consistent.
From the sub-industries, the bio-pharmaceutical section leader, chemical raw plate in the doldrums, but also more realistically reflect the fundamental needs.
Biopharmaceutical strong performance. A flow The spread of the epidemic outbreak of the entire performance of the catalyst plate, plate revenue, gross profit grew significantly higher than the overall level of the industry.
Chemical raw weaker trend. We believe that one is due to Financial Crisis, demand for downstream industries to reduce year on year; the other hand, VA, VE and other vitamins and a variety of anti-infective drug prices of raw materials in varying degrees or lower, resulting in the entire sub-industry of declining profits.
Other plate growth. We believe that support the national pharmaceutical policies on all aspects of pharmaceutical industry chain have direct pulling effect, primary care market, demand in the initial release.
Overall, nearly 1 / 3 of the profits of pharmaceutical companies rapid growth occurs, there is only 10% performance drop.
Mining medical reform and integration of assets subject
We believe that the theme of the 2010 medical plates from short term investment opportunities will be endless, if the focus on the whole, medical reform and assets related to the theme of integration may be more mining space.
Medical reform is the main theme in the pharmaceutical industry. The State Council's "five key health system reform?? 2010 major work," pharmaceutical industry in 2010 will be the trend in real terms to some extent the impact of capital flows on the overall market has a certain significance. Expansion of primary health care markets, such as the implementation of the reform of public hospitals will bring real good company, we mainly recommend varieties include: chemical drugs have Huadong Medicine [25.440.95%], HRH medicine [43.16-1.84%]; brand Traditional Chinese medicine The east and E-Jiao [32.95-1.32%], Yunnanbaiyao [65.11-2.31%], in the constant group [37.60-2.11%], Yi Bai pharmaceutical [22.90-2.68%], Hong America Pharmaceutical [13.10-3.39%] , CR 39 [26.30-2.66%] Tasly [28.41-3.27%], Hong edge of medicine [23.99-3.58%]; biological drugs have Hualan of [72.30-2.30%], Shanghai RAAS [43.36-1.63%]; medical equipment business, and there are Shanghai Pharmaceutical [17.60 -1.84%], diving medical [47.51-2.08%].
We are high quality suppliers, our products such as CP-60 Current Probe , china CRI-1001 Tester for oversee buyer. To know more, please visits test fixture.
Processing your request, Please wait....
